A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence

Completed · Phase 3

Conditions studied: Basal Cell Carcinoma

In brief

The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant therapy, will have an improved cure rate over the ED/C historical norm of approximately 70% at 1-year posttreatment follow-up. A secondary objective is to assess cosmetic outcome.

Key facts

Study ID

NCT00129519

Run by

Graceway Pharmaceuticals, LLC

People needed

63

Starts

2004-01-01

Expected to finish

2006-01-01

Last updated by the study team

2010-07-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Basal cell carcinoma

You may not qualify if…

• Psoriasis

Where it is running

• Study site — Grass Valley, California, United States
• Study site — Loma Linda, California, United States
• Study site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.